AR086907A1 - Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17 - Google Patents

Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17

Info

Publication number
AR086907A1
AR086907A1 ARP120102076A ARP120102076A AR086907A1 AR 086907 A1 AR086907 A1 AR 086907A1 AR P120102076 A ARP120102076 A AR P120102076A AR P120102076 A ARP120102076 A AR P120102076A AR 086907 A1 AR086907 A1 AR 086907A1
Authority
AR
Argentina
Prior art keywords
treatment
psa
patient
psoriatic arthritis
antagonist
Prior art date
Application number
ARP120102076A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR086907A1 publication Critical patent/AR086907A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Métodos predictivos y terapias personalizadas para el tratamiento de artritis psoriásica (PsA). De una manera específica, esta divulgación se refiere a métodos para el tratamiento de un paciente que tenga artritis psoriásica (PsA) mediante la administración, selectivamente, de un antagonista de IL-17, por ejemplo, un anticuerpo de IL-17, tal como secukinumab, al paciente con artritis psoriásica (PsA), con base en que el paciente tenga una predisposición a tener una respuesta favorable al tratamiento con el antagonista de IL-17. También en la presente se dan a conocer métodos de diagnóstico útiles para predecir la probabilidad de que un paciente que tenga artritis psoriásica (PsA) responderá al tratamiento con un antagonista de IL-17, por ejemplo, con un anticuerpo de IL-17, tal como secukinumab.Reivindicación 20: Un antagonista de IL-17 para utilizarse en el tratamiento de artritis psoriásica (PsA), caracterizado porque se administra al paciente una cantidad terapéuticamente efectiva del antagonista de IL-17, con base en que el paciente tenga un alelo de artritis psoriásica (PsA) con respuesta, o con base en que el paciente no tenga un alelo de artritis psoriásica (PsA) sin respuesta.
ARP120102076A 2011-11-21 2012-06-11 Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17 AR086907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IQ3702011 2011-11-21
US201261624564P 2012-04-16 2012-04-16

Publications (1)

Publication Number Publication Date
AR086907A1 true AR086907A1 (es) 2014-01-29

Family

ID=48470189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102076A AR086907A1 (es) 2011-11-21 2012-06-11 Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17

Country Status (12)

Country Link
US (1) US20150064193A1 (es)
EP (1) EP2783014A1 (es)
JP (1) JP2015504430A (es)
KR (1) KR20140097178A (es)
CN (1) CN104011223A (es)
AR (1) AR086907A1 (es)
AU (1) AU2012341081B2 (es)
BR (1) BR112014012101A2 (es)
CA (1) CA2856252A1 (es)
MX (1) MX2014006158A (es)
RU (1) RU2014125071A (es)
WO (1) WO2013077907A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3501550A1 (en) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10039810B2 (en) 2014-05-15 2018-08-07 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016038538A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
TW201639596A (zh) * 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
WO2017072183A1 (en) 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
KR20210093973A (ko) * 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
MA56124A (fr) * 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
AU2020347952A1 (en) * 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
WO2022190034A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CN114427001A (zh) * 2022-01-29 2022-05-03 中日友好医院(中日友好临床医学研究所) 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP3366702B1 (en) 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
CN102617735B (zh) 2008-09-29 2015-09-09 罗氏格黎卡特股份公司 针对人il17的抗体及其应用
CN102576015B (zh) * 2009-07-28 2014-09-10 詹森生物科技公司 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物
CN107029234A (zh) * 2010-10-08 2017-08-11 诺华有限公司 利用il‑17拮抗剂治疗牛皮癣的方法
AR084234A1 (es) * 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)

Also Published As

Publication number Publication date
US20150064193A1 (en) 2015-03-05
AU2012341081A1 (en) 2014-05-29
CN104011223A (zh) 2014-08-27
AU2012341081B2 (en) 2015-06-04
BR112014012101A2 (pt) 2019-09-24
RU2014125071A (ru) 2015-12-27
JP2015504430A (ja) 2015-02-12
WO2013077907A1 (en) 2013-05-30
EP2783014A1 (en) 2014-10-01
KR20140097178A (ko) 2014-08-06
MX2014006158A (es) 2014-06-19
CA2856252A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
AR086907A1 (es) Metodos para el tratamiento de artritis psoriasica utilizando antagonistas de il-17
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
ECSP14004893A (es) Moléculas de unión para bcma y cd3
AR052056A1 (es) Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
AR084234A1 (es) Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
NI201300057A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
GT201300215A (es) Inhibidores de glucosilceramida sintasa
PE20081501A1 (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2011001760A1 (es) Combinación que comprende metotrexato y un inhibidor de dhodh no hepatotóxico; y uso en el tratamiento de enfermedades tales como artritis psoriatica, esclerosis multiple, psoriasis, entre otras.
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
CR20150153A (es) Tratamiento para artitris reumatoide
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112014027991A2 (pt) agentes para neutralização de influenza
AR092981A1 (es) Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero
AR090738A1 (es) Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
AR066416A1 (es) Catalizador de deshidrogenacion, proceso de preparacion del mismo y proceso de deshidrogenacion de un hidrocarburo
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares

Legal Events

Date Code Title Description
FA Abandonment or withdrawal